Stock Ticker

  • Loading stock data...

Merck (NYSE:MRK) Makes Investment In Seattle Genetics Inc. (NASDAQ:SGEN) For Development Of Ladiratuzumab Vedotin

Merck (NYSE:MRK) has entered a development agreement for Seattle Genetics Inc. (NASDAQ:SGEN) ladiratuzimab vedotin antibody-drug conjugate (ADC). Merck joins Gilead in investing in ADC-developer with a stake in Seattle Genetics The agreement came hours after Gilead Sciences Inc. (NYSE:GILD) announced the acquisition of Immunomedics for $21 billion. The centerpiece of Gilead’s deal is Immunomedic’s anti-Trop-2 […]

Gilead Sciences, Inc. (NASDAQ:GILD) Reports Minor Benefits Of Remdesivir In COVID-19 Patients

Gilead Sciences, Inc. (NASDAQ:GILD) released an update about its developmental COVID-19 vaccine remdesivir, revealing that the treatment yielded modest improvements in patients. Coronavirus patients who were administered with remdesivir intravenously for five days demonstrated moderate improvements. However, the COVID-19 patients that were treated with the drug for 10-days did not yield significant improvements. Remdesivir was […]

Gilead Sciences, Inc (NASDAQ:GILD) Speaks Out On The Trial Of Its Remdesivir Drug

Gilead Sciences, Inc (NASDAQ:GILD) is pleased to report about the success it is witnessing with its vaccine Remdesivir. The scientists have been working on the product in the hope that it would turn out to be the vaccine that would possibly help in dealing with COVID-19. Gilead has given an update outlining that it is […]

Gilead Sciences Inc. (NASDAQ:GILD) Commences Two Phase 3 Clinical Trials of Remdesivir For COVID-19 Treatment

Gilead Sciences Inc. (NASDAQ:GILD) has announced that it is expanding clinical trials for its antiviral drug remdesivir as a potential treatment of COVID-19 in countries outside China. Gilead to expand clinical trials of remdsivir to other countries outside china The company now expects to begin two new remdesivir clinical trials in March across Asia and […]

Plandai Biotechnology Inc (OTCMKTS:PLPL) Extends Its Association With USN (EDXC, GILD)

Plandai Biotechnology Inc (OTCMKTS:PLPL) reported that Ultimate Sports Nutrition is designing a new product line targeting the New Zealand and Australian markets. This line of products will be formulated using company’s patented Phytofare® complex. As per the new contract, the USN can assess the applications of the Phytofare® with other contract manufacturers. The idea is […]

Plandai Biotechnology Inc (OTCMKTS:PLPL) And ENDEXX CORP (OTCMKTS:EDXC) Plunges, Gilead Sciences, Inc. (NASDAQ:GILD) Consolidates

On Friday’s trading session, Plandai Biotechnology Inc (OTCMKTS:PLPL) and ENDEXX CORP (OTCMKTS:EDXC) declined 10.56% and 6.54%, respectively to close the week in deep red. However, major biotech firm Gilead Sciences, Inc. (NASDAQ:GILD) managed to halt its decline and consolidated to close almost flat at $107.78. The buzz Plandai Biotechnology earlier disclosed that Ultimate Sports Nutrition […]

Gilead Sciences, Inc. (NASDAQ:GILD) Wins Street’s Hearts With Competitive Hepatitis C Drug Pricing

Boston, MA 10/13/2014 (wallstreetpr) – Gilead Sciences, Inc. (NASDAQ:GILD) is expected to reflect the positivity of the last week in its share prices today as well. The pharma company achieved a major milestone two days back when it recieved the U.S. Food and Drug Administration (FDA)’s nod for its hepatitis C drug. The regulatory approval […]

Gilead Sciences, Inc. (NASDAQ:GILD) Set To Hike Its New Hepatitis C Drug Price

Boston, MA 09/15/2014 (wallstreetpr) – Biopharmaceutical company, Gilead Sciences, Inc. (NASDAQ:GILD) is set to lift the price of its next generation edition of hepatitis C drug. The company has already been facing pressures of higher costs from the insurers and the latest move meant that the treatment would be more expensive than ever before. To […]

The Price of Sovaldi Produced By Gilead Sciences, Inc. (NASDAQ:GILD) Touches New Heights With $84,000 Price Tag

Boston, MA 08/20/2014 (wallstreetpr) – The inflation in pharmaceutical sector may not be touching eye-popping figures, but $84,000 price tag on Sovaldi drug produced by Gilead Sciences, Inc. (NASDAQ:GILD) tells a different story altogether. Most of the US lawmakers and health science experts earlier claimed that the treatment of hepatitis C will not hurt the […]

Deutsche Bank Believes Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Execution Is Improving

Boston, MA 08/19/2014 (wallstreetpr) – Biopharmaceutical company Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) had received a favorable comment from Deutsche Bank analyst on the improvement of its execution of clinical trial, which was one of the key concerns until recently. Positive Comment The investment advisor’s analyst, Alethia Young, viewed the recent appointment of a fresh CMO as […]

With the EPS estimates Vaulted by 21.4% in Past 60 Days, Gilead Sciences, Inc. (NASDAQ:GILD) Is Looking Solid For The Next Quarter

Boston, MA 08/13/2014 (wallstreetpr) – In amidst of most of the companies that are struggling to survive in the market, Gilead Sciences, Inc. (NASDAQ:GILD) looks rock-solid for rest of the year. It has done tremendously well in past few months, and investors are hoping it to continue the good work in coming months as well. […]

Gilead Sciences, Inc. (NASDAQ:GILD) Still Buyable Amid Insiders Selling

Boston, MA 07/03/2014 (wallstreetpr) – Gilead Sciences, Inc. (NASDAQ:GILD) is a research-based drug company that is engaged in the development and commercialization of medicines. The company is behind the expensive but highly recommended hepatitis C treatment known as Sovaldi. The drug hit the market in January and costs $84,000 for treatment. A number of insiders […]

Gilead Sciences, Inc. (NASDAQ:GILD): At Risk Of Rejection

Boston, MA 06/19/2014 (wallstreetpr) – Gilead Sciences, Inc. (NASDAQ:GILD) was having the best of times from last some months. But now it seems the real problem for the company is soon going to start. Its Sovaldi treatment is at the risk of rejection from the U.K. Cost Regulators. The regulator has made it clear that […]

Merck & Co. Inc. (NYSE:MRK) Open To Buying Big Acquisitions

Boston, MA 06/13/2014 (wallstreetpr) – Merck & Co. Inc. (NYSE:MRK) research Chief Roger Perlmutter has stated that the company is more than open to the idea of buying big acquisitions of biotech companies rather than go forward and obtain drug development technologies. Mr. Perlmutter reiterated the company’s attitude for new deals at the back of […]

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold By An Insider

Boston, MA 06/10/2014 (wallstreetpr) – Research-based bio-pharmaceutical company, Gilead Sciences, Inc. (NASDAQ:GILD) has witnessed an insider selling its share in the open market, though only in small quantity. However, this comes on the heels of a consensus Buy rating among thirty-one analysts from different brokerages. Insider Sells Shares The company’s chief financial officer Robin Washington […]